The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.25
Bid: 44.50
Ask: 46.00
Change: -0.40 (-0.89%)
Spread: 1.50 (3.371%)
Open: 44.60
High: 45.25
Low: 44.50
Prev. Close: 45.10
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans

Mon, 22nd Feb 2021 11:01

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Clear Leisure, up 67% at 2.09 pence, 12-month range 1.25p-2.60p. The technology sector-focused investor raises GBP1.0 million through a placing, with the cash going towards accelerating its cryptocurrency plans. Clear Leisure eyes entry into cloud mining contracts and setting up a new bitcoin mining operation in Italy.

----------

Avacta Group, up 10% at 201.40 pence, 12-month range 13.00p-224.88p. The developer of Affimer biotherapeutics and reagents notes press reports in regard to the UK government's take-up of its lateral flow SARS-CoV-2 rapid antigen test. Avacta is now progressing to a full clinical validation with a larger number of patient samples in order to obtain a CE mark for the test for professional use, aiming to bring the test to market

----------

Directa Plus, up 13% at 146.40 pence, 12-month range 46.25p-160.00p. Directa seals a supply agreement and a strategic research & development deal with Nevada, US-based lithium firm NexTech Batteries. The producer and supplier of graphene nanoplatelets based products says the supply agreement has an initial duration of three years, with an option to extend for an additional two years by mutual agreement. The research & development deal also has a duration of three years and provides for joint laboratory activities, with the intention of developing new specific grades of G+ graphene nanoplatelets for a next generation of NexTech's Li-S batteries.

----------

AIM - LOSERS

----------

President Energy, down 15% at 2.07 pence, 12-month range 1.20p-3.90p. The South America-focused energy company expects to post a revenue fall of 32% to USD28 million for 2020. Says average net production in 2020 rose 12%, however.

----------

Image Scan Holdings, down 11% at 2.44 pence, 12-month range 1.00p-3.50p. The X-ray imaging firm's order intake is being hurt by Covid-19, particularly in its security segment. Image Scan says large, multi-unit orders are being delayed.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
4 Aug 2021 17:53

IN BRIEF: Shipment of Avacta's Covid-19 lateral flow test starts

IN BRIEF: Shipment of Avacta's Covid-19 lateral flow test starts

Read more
14 Jul 2021 11:30

AIM WINNERS & LOSERS: Tern raises GBP6 million; Kromek revenue down

AIM WINNERS & LOSERS: Tern raises GBP6 million; Kromek revenue down

Read more
14 Jul 2021 11:10

IN BRIEF: Avacta wins manufacturer certification for lateral flow test

IN BRIEF: Avacta wins manufacturer certification for lateral flow test

Read more
14 Jul 2021 09:02

Avacta gets ISO certification for Affirmer manufacture and distribution

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced on Wednesday that its life sciences diagnostics division has achieved ISO 13485 certification on the quality management system for the manufacture and distribution of 'Affimer' reagents, for use in lateral flow, ELISA and immunodiagnostic in-vitro diagnostic devices.

Read more
29 Jun 2021 12:12

IN BRIEF: Avacta's lateral flow test detects Covid Delta variant

IN BRIEF: Avacta's lateral flow test detects Covid Delta variant

Read more
29 Jun 2021 11:37

AIM WINNERS & LOSERS: Avacta virus test works; React virus boost ebbs

AIM WINNERS & LOSERS: Avacta virus test works; React virus boost ebbs

Read more
29 Jun 2021 08:36

Avacta rapid Covid-19 test detects Delta variant in study

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group announced on Tuesday that a study has shown that its 'AffiDX' antigen lateral flow test detects the 'Delta' variant of the SARS-CoV-2 virus in clinical samples.

Read more
23 Jun 2021 10:28

AIM WINNERS & LOSERS: Mercantile Ports jumps on pact; Avacta recovers

AIM WINNERS & LOSERS: Mercantile Ports jumps on pact; Avacta recovers

Read more
21 Jun 2021 19:24

IN BRIEF: Avacta signs distribution deal for its Covid test

IN BRIEF: Avacta signs distribution deal for its Covid test

Read more
21 Jun 2021 16:11

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
21 Jun 2021 08:37

Avacta enters non-exclusive distribution deal for Covid-19 test

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has entered into a non-exclusive distribution agreement with life science products company Calibre Scientific, it announced on Monday, for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use in the UK and the European Economic Area (EEA).

Read more
11 Jun 2021 12:27

Avacta to sell rapid Covid-19 test in EU following registration

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has received notice of registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test in the European Union, allowing it to place the product on the market for professional use in all 27 countries of the EU.

Read more
11 Jun 2021 11:40

Avacta Covid lateral flow test gets regulatory green light in EU

Avacta Covid lateral flow test gets regulatory green light in EU

Read more
7 Jun 2021 11:31

IN BRIEF: Avacta Covid lateral flow test gets regulatory green light

IN BRIEF: Avacta Covid lateral flow test gets regulatory green light

Read more
7 Jun 2021 10:11

Avacta gets MHRA registration for rapid Covid-19 test

(Sharecast News) - Diagnostics and cancer therapy developer Avacta Group announced on Monday that the Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test for Covid-19, allowing it to place the product on the market in the UK for professional use.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.